P. Zinzani

M. Baccarani, P. Zinzani, R. Conte, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma.

M. Baccarani, V. Poletti, P. Zinzani, 2007, Clinical lymphoma & myeloma.

Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas

S. Pileri, M. Baccarani, P. Zinzani, 2005, Leukemia & lymphoma.

Rituximab in primary conjunctiva lymphoma.

P. Zinzani, L. Alinari, V. Stefoni, 2005, Leukemia research.

Effectiveness of Fludarabine, Idarubicin and Cyclophosphamide (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin's Lymphoma

S. Pileri, M. Baccarani, P. Zinzani, 2004, Leukemia & lymphoma.

Utility of surgical resection with or without radiation therapy in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma.

M. Baccarani, P. Zinzani, E. Barbieri, 2003, Haematologica.

Expression of B-lymphocyte-associated transcription factors in human T-cell neoplasms.

S. Pileri, T. Marafioti, S. Ascani, 2003, The American journal of pathology.

Pathobiology of Primary Mediastinal B-Cell Lymphoma

P. Gaulard, F. Cavalli, S. Pileri, 2003, Leukemia & lymphoma.

Extranodal Marginal Zone B-cell Lymphoma of MALT-type of the Lung: Single-center Experience with 12 Patients

S. Pileri, M. Baccarani, V. Poletti, 2003, Leukemia and Lymphoma.

Advantages of Positron Emission Tomography (PET) with Respect to Computed Tomography in the Follow-up of Lymphoma Patients with Abdominal Presentation

M. Baccarani, P. Zinzani, P. Zinzani, 2002, Leukemia & lymphoma.

Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy.

M. Gobbi, F. Gherlinzoni, B. Falini, 2001, Haematologica.

MACOP-B Regimen Followed by Involved-Field Radiation Therapy in Early-Stage Aggressive Non-Hodgkin's Lymphoma Patients: 14-Year Update Results

S. Pileri, F. Gherlinzoni, P. Zinzani, 2001, Leukemia & lymphoma.

Identification of the B-cell tumor-specific molecular fingerprint using non-radiolabelled PCR consensus primers.

S. Pileri, R. Maffei, P. Zinzani, 2001, Annals of Oncology.

The pathologist's view point. Part I--indolent lymphomas.

S. Pileri, B. Falini, S. Ascani, 2000, Haematologica.

T-cell prolymphocytic leukaemia: does the expression of CD8+ phenotype justify the identification of a new subtype? Description of two cases and review of the literature.

S. Pileri, F. Gherlinzoni, B. Falini, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Diagnostic role of gallium scanning in the management of lymphoma with mediastinal involvement.

F. Gherlinzoni, G. Frezza, R. Franchi, 1999, Haematologica.

Ultrasound-guided core-needle biopsy is effective in the initial diagnosis of lymphoma patients.

S. Pileri, F. Gherlinzoni, S. Ascani, 1998, Haematologica.

Anaplastic large cell lymphoma Hodgkin's-like: a randomized trial of ABVD versus MACOP-B with and without radiation therapy.

S. Pileri, M. Gobbi, F. Gherlinzoni, 1998, Blood.

Primary Mediastinal B-cell lymphoma with sclerosis: clinical and therapeutic evaluation of 22 patients.

F. Gherlinzoni, G. Frezza, P. Zinzani, 1996, Leukemia & lymphoma.

FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low‐grade non‐Hodgkin's lymphoma

P. Zinzani, S. Tura, M. Bendandi, 1995, European journal of haematology.

Hairy cell leukemia

S. Pileri, M. Baccarani, P. Zinzani, 2010, Cancer.

Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia.

R. Foà, P. Zinzani, L. Baldini, 2001, Haematologica.

The importance of assessing blood tumour burden in cutaneous T‐cell lymphoma

J. Scarisbrick, P. Zinzani, J. Nicolay, 2020, The British journal of dermatology.

The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma

M. Federico, P. Zinzani, G. Specchia, 2015, Leukemia & lymphoma.

MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients.

S. Pileri, M. Baccarani, S. Fanti, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.

A. Rossi, P. Zinzani, E. Brusamolino, 2009, Clinical lymphoma & myeloma.

A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.

S. Pileri, M. Baccarani, S. Fanti, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation.

H. Stein, D. Huglo, R. Marcus, 2007 .

Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients.

M. Baccarani, P. Zinzani, L. Alinari, 2005, Haematologica.

Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients.

S. Pileri, F. Mandelli, E. Pescarmona, 1999, Blood.

High-dose therapy followed by autologous bone marrow transplantation in previously untreated high grade non-Hodgkin's lymphoma: 10-year long-term results.

F. Gherlinzoni, P. Zinzani, S. Tura, 1995, European journal of cancer.

MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas.

S. Pileri, P. Mazza, B. Falini, 1995, Leukemia & lymphoma.

Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.

F. Gherlinzoni, P. Zinzani, P. Zinzani, 1994, Haematologica.

T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication.

T. Molina, D. de Jong, S. Pileri, 2001, Gastroenterology.

The importance of endoscopic ultrasonography in the management of low‐grade gastric mucosa‐associated lymphoid tissue lymphoma

S. Pileri, P. Zinzani, P. Zinzani, 2002, Alimentary pharmacology & therapeutics.

Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma

S. Pileri, P. Pauwels, P. Zinzani, 2021, Cancer.

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.

P. Zinzani, I. Bondarenko, Tongyu Lin, 2021, The Lancet. Oncology.

Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma

A. Santoro, P. Zinzani, S. Leppä, 2021, Clinical lymphoma, myeloma & leukemia.

Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab

F. D'Alo', A. Santoro, P. Zinzani, 2021, Journal of translational medicine.

Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients

M. Boaron, C. Nanni, S. Fanti, 2019, Leukemia and Lymphoma.

Prognostic models for primary mediastinal (thymic) B‐cell lymphoma derived from 18‐FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study

P. Zinzani, L. Ceriani, M. Martelli, 2017, British journal of haematology.

Non-Hodgkin's Lymphoma as Adjunct to Induction VNCOP-B Treatment of Elderly High-Grade Randomized Trial With or Without Granulocyte Colony-Stimulating Factor

M. Gobbi, G. Leone, P. Zinzani, 2013 .

Diagnostic role of 18 F-FDG pet in gastric malt lymphoma

A. Alavi, V. Ambrosini, C. Nanni, 2006 .

Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity

A. Stracciari, P. Zinzani, P. Cortelli, 2021, Journal of Neurology.

Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study

M. Baccarani, V. Pavone, P. Zinzani, 2013, Hematological oncology.

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

D. Esseltine, B. Coiffier, P. Zinzani, 2012, Journal of Hematology & Oncology.

Nucleoside Analogs in the Therapy of T-Cell Malignancies

P. Zinzani, V. Gandhi, 2013 .

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.

S. Pileri, M. Baccarani, P. Zinzani, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacogenetics and Proteomics of Anticancer Drugs in Non-Hodgkin's Lymphoma

F. D. De Braud, P. Zinzani, R. Danesi, 2003, Leukemia & lymphoma.

CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified

S. Pileri, E. Sabattini, P. Zinzani, 2010, Journal of Clinical Pathology.

CDKN 1 B / p 27 expression in peripheral T cell lymphoma not otherwise specified

S. Pileri, E. Sabattini, P. Zinzani, 2022 .

Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma.

G. Castellani, S. Pileri, P. Zinzani, 2007, Oncology reports.

Efﬁcacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia

P. Zinzani, L. Baldini, F. Forconi, 2001 .

NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY

K. Savage, U. Jaeger, M. Shipp, 2021, Hematological Oncology.

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.

R. Advani, J. Connors, K. Savage, 2021, The Lancet. Haematology.

Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis.

M. Pfreundschuh, M. Loeffler, P. Zinzani, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?

M. Gobbi, F. Gherlinzoni, F. Mandelli, 1999, Haematologica.

Follicular lymphoma: the diminishing role of chemotherapy

P. Zinzani, B. Casadei, L. Nanni, 2022, Journal of Cancer Metastasis and Treatment.

Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma.

R. Foà, M. Baccarani, T. Barbui, 2002, Blood.

Role of FDG-PET As Prognostic Indicator in Patients with Follicular Lymphoma(FL) After Immunochemotherapy Induction. A Retrospective Study From the Fondazione Italiana Linfomi

A. Levis, M. Federico, P. Zinzani, 2011 .

The Use of FDG-PET in the Initial Staging of Patients with Follicular Lymphoma (FL). A Retrospective Study From the Fondazione Italiana Linfomi

M. Federico, S. Hohaus, G. Gaidano, 2011 .

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

K. Savage, Y. Oki, J. Radford, 2018, New England Journal of Medicine.

INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS

G. Salles, J. Radford, H. Tilly, 2017 .

VNCOP-B regimen in the treatment of high-grade non-Hodgkin's lymphoma in the elderly.

F. Gherlinzoni, P. Mazza, P. Zinzani, 1993, Haematologica.

Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.

B. Coiffier, H. Gómez, P. Zinzani, 2012, The Lancet. Oncology.

Controversies in the Treatment of Peripheral T-cell Lymphoma

P. Gaulard, P. Zinzani, L. de Leval, 2020, HemaSphere.

Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial.

K. Savage, P. Zinzani, S. Horwitz, 2013 .

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.

S. Pileri, M. Baccarani, E. Sabattini, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma.

S. Pileri, M. Baccarani, P. Zinzani, 2005, Haematologica.

Intravascular Large B-cell Lymphoma Successfully Treated with Autologous Transplantation.

P. Zinzani, A. Broccoli, V. Stefoni, 2021, Clinical lymphoma, myeloma & leukemia.

Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma.

R. Foà, M. Baccarani, T. Barbui, 2005, Blood.

Brentuximab vedotin in the treatment of relapsed/refractory CD30+ peripheral T‐cell lymphoma: A FIL phase 2 study

P. Zinzani, P. Corradini, S. Volpetti, 2022, Hematological oncology.

Consensus conferences : guidelines on malignant lymphoma . part 2 : marginal zone lymphoma , mantle cell lymphoma , peripheral T-cell lymphoma

N. Schmitz, E. Iannitto, P. Zinzani, 2013 .

Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

P. Zinzani, G. Meloni, G. Barosi, 2006, Haematologica.

Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway

S. Pileri, P. Zinzani, G. Inghirami, 2014, Leukemia.

Posttransplant lymphoproliferative disorders in liver transplanted patients: a report of four cases.

S. Pileri, M. Baccarani, P. Zinzani, 2006, Transplantation proceedings.

Importance of gallium scan restaging for curative treatment of mediastinal lymphomas.

M. Baccarani, S. Fanti, P. Zinzani, 2001, Haematologica.

Early relapse in a patient with Hodgkin’s disease and negative interim FDG-PET

V. Ambrosini, C. Nanni, D. Rubello, 2008, Annals of nuclear medicine.

Discordant response to chemotherapy: An unusual patternof fluoro-deoxy-d-glucose uptake in heavily pre-treated lymphoma patients

V. Ambrosini, C. Nanni, D. Rubello, 2006, Leukemia & lymphoma.

Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report

C. Nanni, P. Zinzani, M. Cavo, 2018, Leukemia & lymphoma.

Microplastics shape the ecology of the human gastrointestinal intestinal tract

S. Rampelli, S. Turroni, P. Brigidi, 2021, Current Opinion in Toxicology.

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

J. Rossi, E. Jaffe, N. Munshi, 2018, Blood.

Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice

P. Zinzani, G. Rossi, S. Tura, 2015, Leukemia & lymphoma.

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

J. Vose, M. Czuczman, H. Tilly, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

M. Ghielmini, P. Zinzani, G. Martinelli, 2012, Haematologica.

The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non‐Hodgkin lymphoma of distinct histological origin

J. Vose, M. Czuczman, P. Zinzani, 2011, British journal of haematology.

Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B‐cell non‐Hodgkin lymphoma

M. Baccarani, S. Fanti, P. Zinzani, 2008, Cancer.

Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).

S. Pileri, M. Gobbi, M. Baccarani, 2008, The Lancet. Oncology.

A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium‐90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non‐Hodgkin lymphoma

M. Baccarani, S. Fanti, P. Zinzani, 2008, Cancer.

VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly

S. Pileri, M. Baccarani, P. Zinzani, 2007, Leukemia & lymphoma.

Gemcitabine as frontline treatment for cutaneous T‐cell lymphoma

S. Pileri, M. Baccarani, L. Pagano, 2005, Cancer.

Gemcitabine as Frontline Treatment for Cutaneous

S. Pileri, M. Baccarani, L. Pagano, 2005 .

Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.

F. Gherlinzoni, P. Zinzani, S. Tura, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bilateral Primary Breast Lymphoma: A Case of Local Recurrence

M. Baccarani, P. Zinzani, L. Alinari, 2003, Leukemia & lymphoma.

Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma.

P. Zinzani, M. Dreyling, B. Childs, 2013, Clinical advances in hematology & oncology : H&O.

Autologous Hematopoietic Stem Cell Transplantation in Non-Hodgkin’s Lymphomas

P. Zinzani, 2005, Acta Haematologica.

Genetics and clinical phenotype of Erdheim–Chester disease: A case report of constrictive pericarditis and a systematic review of the literature

P. Rucci, P. Zinzani, C. Pizzi, 2022, Frontiers in Cardiovascular Medicine.

Long‐term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B‐cell lymphoma patients

S. Pileri, P. Zinzani, E. Derenzini, 2013, Hematological oncology.

Primary bone lymphoma: evaluation of chemoimmunotherapy as front-line treatment in 21 patients.

S. Pileri, M. Baccarani, P. Zinzani, 2011, Clinical lymphoma, myeloma & leukemia.

EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma.

A. Santoro, P. Zinzani, A. Engert, 2006, Clinical lymphoma & myeloma.

Chlorambucil plus rituximab with or without maintenance rituximab as first‐line treatment for elderly chronic lymphocytic leukemia patients

R. Foà, S. Molica, S. Chiaretti, 2014, American journal of hematology.

To the editor: Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial

P. Zinzani, A. Rocco, A. Chiappella, 2017 .

Expression of CD52 in peripheral T-cell lymphoma.

S. Pileri, P. Zinzani, P. Piccaluga, 2007, Haematologica.

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study

R. Foà, S. Molica, G. Gaidano, 2021, Cancers.

Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma

P. Zinzani, G. Minotti, 2021, Journal of Cancer Research and Clinical Oncology.

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

C. Buske, G. Gaidano, P. Zinzani, 2019, Blood.

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data

M. Weichenthal, R. Dummer, O. Akilov, 2021, Blood advances.

Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease.

P. Zinzani, A. Broccoli, L. Argnani, 2017, Cancer treatment reviews.

Local versus systemic treatment for primary cutaneous B-cell lymphoma.

P. Zinzani, A. Broccoli, L. Argnani, 2010, Clinical lymphoma, myeloma & leukemia.

Chemotherapy in cutaneous T-cell lymphoma

P. Zinzani, N. Pimpinelli, R. Alterini, 2009 .

Primary cutaneous B-cell lymphoma - Reply

S. Pileri, A. Pileri, S. Chimenti, 2006 .

Emerging New Small Molecules in Peripheral T‐cell Lymphomas

P. Zinzani, A. Broccoli, 2021 .

Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience.

P. Zinzani, M. Cavo, V. Stefoni, 2019, Clinical lymphoma, myeloma & leukemia.

Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine.

S. Pileri, M. Baccarani, P. Zinzani, 2004, Haematologica.

Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine.

S. Pileri, P. Zinzani, S. Tura, 2000, Haematologica.

The safety and clinical effectiveness of rapid infusion with CT‐P10 in patients with non‐Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non‐interventional post‐authorization safety study in Europe

G. Salles, P. Zinzani, A. Tucci, 2022, Hematological oncology.

Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma.

J. Connors, L. Specht, P. Zinzani, 2018 .

Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop.

F. d'Amore, P. Zinzani, P. Zinzani, 2008, European journal of cancer.

Interesting activity of pegylated liposomal doxorubicin in primary refractory and multirelapsed Hodgkin lymphoma patients: bridge to transplant

P. Zinzani, B. Casadei, C. Pellegrini, 2018, Hematological oncology.

Sequential Double Bridging to Transplant with Diversified Anti- PD1 Monoclonal Antibodies Retreatment in Relapsed Hodgkin Lymphoma: A Case Report

P. Zinzani, M. Cavo, C. Cellini, 2018 .

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program.

J. Radford, P. Zinzani, A. Gautam, 2016, Critical reviews in oncology/hematology.

Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi‐relapsed Hodgkin's lymphoma

S. Pileri, P. Zinzani, R. Maglie, 2016, Hematological oncology.

Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update

E. Kimby, B. Cheson, P. Zinzani, 2015, Leukemia & lymphoma.

Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents

P. Zinzani, P. Corradini, A. Pinto, 2015, Leukemia & lymphoma.

Radioimmunotherapy Confers Long-Term Survival to Lymphoma Patients with Acceptable Toxicity: Registry Analysis by the International Radioimmunotherapy Network

P. Zinzani, L. Trümper, C. Suh, 2011, The Journal of Nuclear Medicine.

Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series

P. Zinzani, M. Carella, M. Gentilini, 2022, Tumori.

PD-1 blockade as bridge to allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series

P. Zinzani, M. Cavo, M. Carella, 2019, Haematologica.

Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies

M. Federico, P. Zinzani, U. Vitolo, 2014, Leukemia & lymphoma.

The role of surgery for haematologic neoplasms of bone.

P. Zinzani, A. Mavrogenis, P. Ruggieri, 2012, Acta orthopaedica Belgica.

Primary Mediastinal Large B‐Cell Lymphoma

P. Zinzani, 2014 .

Radioimmunotherapy as the first line of treatment in non-Hodgkin lymphoma.

P. Zinzani, N. Rezaei, Mahsa Eskian, 2018, Immunotherapy.

Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma.

S. Fanti, P. Zinzani, E. Derenzini, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Overview of alemtuzumab therapy for the treatment of T-cell lymphomas

P. Zinzani, A. Gallamini, G. Rossi, 2012, Leukemia & lymphoma.

Enteropathy-associated T-cell lymphoma.

S. Pileri, P. Zinzani, A. Ferreri, 2011, Critical reviews in oncology/hematology.

The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study

P. Zinzani, G. Rossi, U. Vitolo, 2017, Leukemia & lymphoma.

Malignant Lymphomas Primary mediastinal large B-cell lymphoma with sclerosis : a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy

M. Gobbi, P. Zinzani, M. Martelli, 2022 .

Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups

A. Levis, P. Zinzani, P. Valagussa, 2008 .

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

G. Salles, I. Flinn, C. Flowers, 2017, Haematologica.

Phase II Trial of Short-Course R-Chop Followed by 90 Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients

S. Pileri, M. Baccarani, S. Fanti, 2010 .

Apoptosis induction with three nucleoside analogs on freshly isolated B‐chronic lymphocytic leukemia cells

P. Zinzani, G. Martinelli, P. Tosi, 1994, American journal of hematology.

FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.

P. Zinzani, P. Zinzani, E. Ottaviani, 1994, Leukemia.

A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL

L. Staudt, R. Gascoyne, G. Salles, 2014 .

Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network

P. Zinzani, L. Trümper, K. Hohloch, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

Lymphoproliferative lung disorders.

V. Poletti, P. Zinzani, M. Chilosi, 2005, Seminars in respiratory and critical care medicine.

Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient.

S. Pileri, P. Zinzani, C. Agostinelli, 2014, Clinical lymphoma, myeloma & leukemia.

Gene expression analysis of peripheral T-cell lymphoma not otherwise specified reveals two distinct subgroups and recurrent PDGFRα deregulation

S. Pileri, B. Falini, P. Zinzani, 2006 .

Primary follicular lymphoma of the testis in childhood: an entity with peculiar clinical and molecular characteristics

S. Pileri, B. Falini, G. Gaidano, 2002, Journal of clinical pathology.

The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee.

L. Staudt, W. Chan, W. Wilson, 2022, Blood.

Frontline Siltuximab and Rituximab in TAFRO syndrome: A case report

P. Zinzani, M. Marchetti, E. Feyles, 2020, European journal of haematology.

Erythematous induration of the chest

A. Pileri, P. Zinzani, F. Bacci, 2015, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma.

M. Baccarani, P. Zinzani, L. Alinari, 2005, Haematologica.

Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report

P. Zinzani, B. Casadei, C. Pellegrini, 2021, Tumori.

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

Michael L. Wang, O. Casasnovas, P. Zinzani, 2019, Leukemia.

An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis. A case report and a review of literature.

P. Zinzani, C. Agostinelli, E. Derenzini, 2013, Anticancer research.

Anaplastic Large Cell Lymphoma : A Critical Reappraisal

S. Pileri, B. Falini, A. Pileri, 2004 .

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

S. Pileri, V. Pavone, S. Hohaus, 2021, Blood.

Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.

F. Angrilli, S. Molica, P. Zinzani, 2016, European journal of cancer.

Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia

S. Sacchi, P. Zinzani, F. Ricci, 2012, Cancer.

Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients

M. Baccarani, P. Zinzani, E. Derenzini, 2013, Leukemia & lymphoma.

Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets.

Stefano A Pileri, Andrea Califano, Katia Basso, 2007, The Journal of clinical investigation.

Radiotherapy in early stage Hodgkin's disease.

F. Gherlinzoni, G. Frezza, P. Mazza, 1994, Leukemia & lymphoma.

OC-0502 Role of consolidation RT to bulky lesions of advanced Hodgkin lymphoma: results of FIL HD0801 trial

V. Pavone, P. Franzone, P. Zinzani, 2019, Radiotherapy and Oncology.

18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma

V. Ambrosini, C. Nanni, S. Fanti, 2006, Leukemia & lymphoma.

BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia

P. Zinzani, M. Fiorentino, C. Agostinelli, 2019, OncoTargets and therapy.

Aggressive lymphoma: improving treatment outcome with rituximab

J. Vose, B. Coiffier, M. Pfreundschuh, 2002, Anti-cancer drugs.

Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET

C. Nanni, D. Rubello, S. Fanti, 2008, Nuclear medicine communications.

In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia

S. Pileri, A. Vitale, P. Pelicci, 2015, Journal of Hematology & Oncology.

Multi-centre, phase II study of combination antibody therapy with epratuzumab plus rituximab in relapsed/refractory indolent and aggressive NHL: Promising preliminary results

T. Lister, P. Zinzani, S. Strauss, 2004 .

PET in T-Cell Lymphoma

P. Zinzani, 2011, Current hematologic malignancy reports.

Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

G. Lenz, A. Santoro, A. Nagler, 2018, Blood.

Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.

A. LaCasce, K. Savage, P. Zinzani, 2018, Journal of Clinical Oncology.

FLAG (fludarabine + cytosine arabinoside + G‐CSF) induces complete remission in acute‐phase chronic myeloid leukaemia: a case report

P. Zinzani, G. Rosti, S. Tura, 1994, British journal of haematology.

Myeloperoxidase expression by histiocytes in Kikuchi's and Kikuchi-like lymphadenopathy.

S. Pileri, B. Falini, S. Ascani, 2001, The American journal of pathology.

How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens fare in the long-term?

M. Gobbi, F. Gherlinzoni, F. Mandelli, 1999 .

Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study

G. Ciliberto, A. Paradiso, F. Baldanti, 2022, Clinical Infectious Diseases.

Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe

G. Salles, P. Zinzani, A. Bosi, 2022, eJHaem.

Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients

S. Pileri, M. Baccarani, S. Fanti, 2010, Clinical Cancer Research.

OPTIMISING SALVAGE THERAPY IN AGGRESSIVE B CELL NON-HODGKIN LYMPHOMA This symposium took place on 7 th October 2016 as a part of the European Society for Medical Oncology ( ESMO ) 2016 Congress in Copenhagen , Denmark

Speakers, F. d'Amore, P. Zinzani, 2016 .

Diagnostic role of 18F-FDG PET in gastric MALT lymphoma.

A. Alavi, V. Ambrosini, C. Nanni, 2006, Nuclear medicine review. Central & Eastern Europe.

Complete molecular remission induced by rituximab in a patient with diffuse large cell lymphoma.

F. Gherlinzoni, P. Zinzani, S. Tura, 2000, Haematologica.

A Phase II Open-Label, Multi-Center Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Patients with Previously Treated Peripheral T-Cell Lymphoma(PTCL)

B. Coiffier, F. d'Amore, J. Radford, 2014 .

Safe and Effective Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) and Low Baseline Platelet Counts with Belinostat

K. Savage, P. Zinzani, S. Horwitz, 2014 .

Phase 3 study of anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in relapsed or refractory cutaneous T-cell lymphoma (CTCL).

L. Hughey, P. Zinzani, T. Kuzel, 2014 .

belinostat In Relapsed Or Refractory Peripheral T-cell Lymphoma (r/r Ptcl) Subtype Angioimmunoblastic T-cell Lymphoma (aitl): Results From The Pivotal Belief Trial : 153

P. Zinzani, S. Horwitz, O. O’Connor, 2013 .

Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma.

E. Iannitto, G. Leone, G. Papa, 1995, Leukemia & lymphoma.

Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low‐grade non‐Hodgkin's lymphoma

F. Gherlinzoni, P. Zinzani, P. Zinzani, 1996, European journal of haematology.

Anthracycline Containing Regimens in Intermediate Grade Lymphoma

F. Mandelli, G. Leone, G. Papa, 1992 .

MN (N = Novantrone) COP-B therapy on high and intermediate grade non-Hodgkin's lymphoma: an alternative to MA (A = adriamycin) COP-B?

S. Pileri, F. Gherlinzoni, P. Mazza, 1991, Haematologica.

Panobinostat As Salvage Treatment for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible to High Dose Therapy: A Phase II Study of the Fondazione Italiana Linfomi (FIL)

S. Pileri, R. Fanin, A. Levis, 2014 .

Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice

P. Zinzani, A. Broccoli, B. Casadei, 2017, Hematological oncology.

PET in natural killer/T-cell lymphoma: the debate continues.

S. Fanti, P. Zinzani, 2015, The Lancet. Haematology.

A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies.

M. Dolled-Filhart, K. Emancipator, P. Zinzani, 2014 .

Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study

K. Savage, M. Shipp, A. Santoro, 2018, Blood.

Cep Regimen (Ccnu, Etoposide, Prednimustine) for Relapsed/Refractory Hodgkin's Disease

F. Gherlinzoni, P. Zinzani, E. Barbieri, 1994, Tumori.

Detection of soluble interleukin‐2 receptor and interleukin‐10 in the serum of patients with aggressive non‐Hodgkin's lymphoma.Identification of a subset at high risk of treatment failure

P. Galieni, G. Papa, P. Zinzani, 1994, Cancer.

In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.

M. Czuczman, C. Nanni, L. Specht, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bendamustine: role and evidence in lymphoma therapy, an overview

B. Cheson, P. Zinzani, E. Derenzini, 2014, Leukemia & lymphoma.

Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).

M. Gobbi, M. Voso, P. Zinzani, 2012, Annals of Oncology.

Late FDG PET Normalization After Radioimmunotherapy in a Patient With Non-Hodgkin Lymphoma

V. Ambrosini, C. Nanni, D. Rubello, 2009, Clinical nuclear medicine.

Continuous infusion of interleukin-2 in two relapsed high grade non-Hodgkin lymphoma patients: effectiveness and tolerability.

P. Zinzani, S. Tura, D. Rondelli, 1991, European journal of cancer.

Radioimmunotherapy with 90Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network

P. Zinzani, G. Wulf, K. Hohloch, 2011, Bone Marrow Transplantation.

Prognostic value of serum IL‐10 and soluble IL‐2 receptor levels in aggressive non‐Hodgkin's lymphoma

P. Galieni, G. Papa, P. Zinzani, 1994, British journal of haematology.

Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia.

F. Bosch, R. Marcus, P. Zinzani, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells.

P. Zinzani, P. Zinzani, E. Ottaviani, 1999, Leukemia & lymphoma.

Loxoribine affects fludarabine activity on freshly isolated B-chronic lymphocytic leukemia cells.

P. Zinzani, P. Zinzani, E. Ottaviani, 1997, Leukemia & lymphoma.

Fludarabine treatment in resistant Waldenstrom's macroglobulinemia

F. Gherlinzoni, P. Zinzani, P. Zinzani, 1995, European journal of haematology.

Induction of "in vitro" apoptosis by fludarabine in freshly isolated B-chronic lymphocytic leukemia cells.

P. Zinzani, G. Martinelli, P. Tosi, 1994, Leukemia & lymphoma.

Fludarabine in patients with advanced and/or resistant B‐chronic lymphocytic leukemia

R. Fanin, P. Galieni, P. Zinzani, 1993, European journal of haematology.

Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma.

R. Fanin, P. Galieni, P. Zinzani, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry

P. Zinzani, C. Suh, K. Hohloch, 2019, Annals of Hematology.

Fludarabine + prednisone ± α-interferon followed or not by α-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study

Mauro, R. Fanin, P. Zinzani, 2003 .

Non-Hodgkin's lymphoma: the evolving role of purine analogues.

P. Zinzani, 2002, Best practice & research. Clinical haematology.

2‐Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders

P. Galieni, P. Zinzani, P. Zinzani, 1997, European journal of haematology.

Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms.

Ash A. Alizadeh, Ryan D. Morin, B. Nadel, 2022, Blood.

Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment

R. Foà, S. Molica, S. Chiaretti, 2011 .

A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis

R. Foà, S. Molica, P. Zinzani, 2010 .

Safety and Efficacy of Bendamustine with or without Rituximab for the Treatment of Heavily Pretreated CLL and Lymphoma Patients. A Multicenter Retrospective Study.

M. Gobbi, G. Gaidano, P. Zinzani, 2009 .

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

A. Berrebi, U. Jaeger, H. Döhner, 2008 .

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

N. Johnson, A. Santoro, P. Zinzani, 2020, Journal of Clinical Oncology.

Successful Pregnancies, Births, and Children Development Following Oocyte Cryostorage in Female Cancer Patients During 25 Years of Fertility Preservation

P. Zinzani, E. Porcu, A. Perrone, 2022, Cancers.

Apoptosis induction with fludarabine on freshly isolated chronic myeloid leukemia cells.

P. Zinzani, G. Martinelli, P. Zinzani, 1994, Haematologica.

FLAG (Fludarabine, Cytarabine, G‐CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects

M. Gobbi, P. Zinzani, E. Ottaviani, 1996, European journal of haematology.

P. Zinzani, G. Martinelli, G. Cimino, 2005 .

P. Zinzani, G. Martinelli, G. Cimino, 1998, Haematologica.

Phase 1-2 Study of Pembrolizumab Combined with the Anti-LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies

P. Zinzani, P. Armand, J. Palcza, 2019, Blood.

Primary non-Hodgkin's lymphoma of the bone: treatment and analysis of prognostic factors for Stage I and Stage II.

P. Zinzani, S. Ferrari, G. Bacci, 2004, International journal of radiation oncology, biology, physics.

LOTIS 2 FOLLOW-UP ANALYSIS: UPDATED RESULTS FROM A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

J. Radford, P. Zinzani, K. Ardeshna, 2021 .

RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

G. Salles, P. Zinzani, M. Winderlich, 2020 .

Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity

M. Ferracin, P. Zinzani, P. Cortelli, 2023, Frontiers in Immunology.

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma

F. Gherlinzoni, P. Mazza, V. Pavone, 2017, Oncotarget.

Efficacy of rituximab in hairy cell leukemia treatment.

S. Pileri, S. Ascani, P. Zinzani, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factor VIII inhibitor prior to and during secondary acute nonlymphocytic leukemia in a patient with cured Hodgkin's disease.

P. Zinzani, P. Zinzani, S. Tura, 1995, Leukemia & lymphoma.

A PIVOTAL, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, TWO‐ARM, PHASE 2 STUDY OF ME‐401 INVESTIGATING TWO DOSING SCHEDULES IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AFTER FAILURE OF TWO OR MORE PRIOR SYSTEMIC THERAPIES

A. Zelenetz, P. Abrisqueta, C. Buske, 2019, Hematological Oncology.

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

G. Salles, I. Flinn, C. Flowers, 2014, The New England journal of medicine.

Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma

P. Zinzani, S. Horwitz, M. Duvic, 2017, Clinical Cancer Research.

Vemurafenib mucosal side‐effect

A. Pileri, P. Zinzani, A. Patrizi, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

R. Advani, J. Briones, G. Salles, 2019, The Lancet.

Peripheral T-cell lymphoma, not otherwise specified.

K. Savage, S. Pileri, P. Zinzani, 2017, Blood.

Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients

S. Pileri, M. Baccarani, B. Falini, 2007, Leukemia.

W. Gradishar, G. Curigliano, F. Esteva, 2019, Drugs.

Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients.

S. Pileri, F. Gherlinzoni, S. Ascani, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

M. Weichenthal, R. Dummer, O. Akilov, 2017, The Lancet.

Peripheral T-cell lymphomas: in “real life” experience are we really improving?

P. Zinzani, 2013, Leukemia & lymphoma.

Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies

S. Pileri, B. Falini, P. Zinzani, 2008, Journal of Clinical Pathology.

Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score.

S. Pileri, B. Falini, S. Ascani, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nodal aggressive non-Hodgkin’s lymphoma in the adult: a review article

S. Pileri, G. Gaidano, P. Zinzani, 2005 .

Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification.

S. Pileri, F. Gherlinzoni, B. Falini, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Targeted molecular therapy in peripheral T-cell lymphomas

S. Pileri, P. Zinzani, P. Piccaluga, 2011, Expert review of hematology.

Peripheral T-cell lymphoma.

J. Vose, R. Gascoyne, P. Zinzani, 2011, Blood.

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

M. Shipp, N. Johnson, J. Radford, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

M. Kersten, P. Riedell, R. Malladi, 2021, Nature Medicine.

Hodgkin's lymphoma: the pathologist's viewpoint.

S. Pileri, H. Stein, B. Falini, 2002, Journal of clinical pathology.

Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients.

F. Gherlinzoni, P. Galieni, S. Molica, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nongastrointestinal mucosa-associated lymphoid tissue (MALT) lymphomas: clinical and therapeutic features of 24 localized patients.

S. Pileri, F. Gherlinzoni, G. Frezza, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens

S. Pileri, E. Sabattini, P. Zinzani, 2006, Journal of Clinical Pathology.

The emerging role of GSK‐3β in the pathobiology of classical Hodgkin lymphoma

S. Pileri, E. Sabattini, P. Zinzani, 2017, Histopathology.

Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

J. Leonard, F. d'Amore, K. Venkatakrishnan, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials

A. Santoro, P. Zinzani, E. Derenzini, 2013, Haematologica.

Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study

K. Savage, M. Shipp, A. Ligon, 2016, The Lancet. Oncology.

Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study

K. Savage, M. Shipp, A. Ligon, 2016, The Lancet. Oncology.

Primary Mediastinal DLBCL: Evolving Biologic Understanding and Therapeutic Strategies

P. Zinzani, P. Piccaluga, 2011, Current oncology reports.

Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins.

P. Gaulard, F. Cavalli, S. Pileri, 2003, The American journal of pathology.

Diffuse large B‐cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification

B. Falini, T. Marafioti, S. Ascani, 2002, Histopathology.

Diffuse large B-cell lymphoma with primary retroperitoneal presentation: clinico-pathologic study of nine cases.

S. Pileri, B. Falini, S. Ascani, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.

K. Savage, B. Coiffier, C. Gisselbrecht, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in In vitro and In vivo Models of T-Cell Lymphoid Malignancies

V. Seshan, P. Zinzani, O. O’Connor, 2010, Clinical Cancer Research.

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

J. Burke, J. Reeves, B. Cheson, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High‐dose therapy followed by autologous bone marrow transplantation (ABMT) in previously untreated non‐Hodgkin's lymphoma

F. Gherlinzoni, P. Mazza, M. Baccarani, 1986, Scandinavian journal of haematology.

RALE051: a novel established cell line of sporadic Burkitt lymphoma

P. Zinzani, G. Martinelli, C. Agostinelli, 2018, Leukemia & lymphoma.

Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper.

M. Federico, A. Santoro, P. Zinzani, 2015, Clinical lymphoma, myeloma & leukemia.

Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays

S. Pileri, M. Negrini, E. Sabattini, 2012, Leukemia.

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

L. Staudt, W. Wilson, L. Sehn, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

L. Staudt, R. Gascoyne, G. Salles, 2017, Clinical Cancer Research.

Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.

S. Pileri, M. Baccarani, P. Zinzani, 2011, Clinical lymphoma, myeloma & leukemia.

Higher response to lenalidomide in relapsed/refractory diffuse large B‐cell lymphoma in nongerminal center B‐cell–like than in germinal center B‐cell–like phenotype

M. Czuczman, S. Pileri, P. Zinzani, 2011, Cancer.

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.

J. Vose, M. Czuczman, R. Bouabdallah, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Consensus conference on the management of tumor lysis syndrome

A. Santoro, P. Zinzani, G. Barosi, 2008, Haematologica.

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.

M. Grever, S. Pileri, M. Berger, 2015, The New England journal of medicine.

[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.

A. López-Guillermo, S. Montoto, F. Cavalli, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation.

S. Pileri, S. Ferrari, A. Califano, 2007, Cancer research.

Alpha‐2b recombinant interferon (Intron) in Hodgkin's lymphoma: Therapeutic perspective

R. Fanin, F. Gherlinzoni, P. Mazza, 1990, European journal of haematology. Supplementum.

Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.

S. Pileri, M. Gobbi, M. Baccarani, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

J. Burke, J. Reeves, I. Flinn, 2021, Blood advances.

Primary intestinal lymphoma: clinical and therapeutic features of 32 patients.

F. Gherlinzoni, P. Zinzani, S. Tura, 1997, Haematologica.

Primary gastric lymphoma: a clinical and therapeutic evaluation of 82 patients.

F. Gherlinzoni, G. Frezza, P. Zinzani, 1995, Leukemia & lymphoma.

Allogeneic stem cell transplantation is capable of healing a case of bone marrow aplasia following CAR-T cell therapy in a lymphoma patient

P. Zinzani, F. Bonifazi, G. Storci, 2022, Leukemia & lymphoma.

Core needle biopsy is effective in the initial diagnosis of mediastinal lymphoma.

F. Gherlinzoni, A. Cancellieri, N. Lacava, 1999, Haematologica.

Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials

O. Casasnovas, P. Gobbi, E. Iannitto, 2020, Cancer medicine.

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

K. Savage, M. Shipp, A. Santoro, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

A. Rossi, A. Levis, P. Zinzani, 2011, The New England journal of medicine.

The pathologist's view point. Part II --aggressive lymphomas.

S. Pileri, B. Falini, S. Ascani, 2000, Haematologica.

Biology and treatment of follicular lymphoma

S. Pileri, E. Sabattini, P. Zinzani, 2009, Expert review of hematology.

Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi.

T. Chisesi, V. Pavone, M. Federico, 2000, Blood.

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

G. Salles, D. Neuberg, M. Shipp, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma

A. Santoro, P. Zinzani, G. Barosi, 2018, Leukemia & lymphoma.

The unique biology and treatment of primary mediastinal B-cell lymphoma.

P. Zinzani, A. Broccoli, 2018, Best practice & research. Clinical haematology.

Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease.

P. Zinzani, A. Broccoli, L. Argnani, 2017, Cancer treatment reviews.

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.

R. Houot, J. Ritz, M. Perales, 2017, Blood.

CD38, BCL‐2, PD‐1, and PD‐1L expression in nodal peripheral T‐cell lymphoma: Possible biomarkers for novel targeted therapies?

S. Pileri, R. Fanin, E. Sabattini, 2017, American journal of hematology.

Optimizing Outcomes in Primary Mediastinal B-cell Lymphoma.

P. Zinzani, A. Broccoli, 2016, Hematology/oncology clinics of North America.

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.

R. Gascoyne, C. Steidl, S. Pileri, 2016, The Lancet. Haematology.

Results in hairy‐cell leukemia patients treated with α‐interferon: Predictive prognostic factors

S. Pileri, E. Sabattini, P. Zinzani, 1992 .

Novel Therapies for Aggressive B-Cell Lymphoma

K. Takeshita, P. Zinzani, K. Foon, 2012, Advances in hematology.

Nonpeghylated liposomal doxorubicin combination regimen (R‐COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity

F. Angrilli, A. Santoro, P. Zinzani, 2020, Hematological oncology.

Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.

E. Giovannetti, F. Crea, P. Zinzani, 2009, Critical reviews in oncology/hematology.

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.

J. Radford, P. Zinzani, K. Ardeshna, 2021, The Lancet. Oncology.

Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience.

F. Gherlinzoni, G. Frezza, P. Zinzani, 1999, Leukemia & lymphoma.

Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).

A. López-Guillermo, F. Cavalli, P. Zinzani, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.

R. Dummer, O. Akilov, P. Zinzani, 2020, European journal of cancer.

Italian Real-Life Experience on the Use of Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas

C. Massone, A. Pileri, A. Giordano, 2022, Cancer management and research.

CMAR_A_377015 3205..3221

C. Massone, A. Pileri, A. Giordano, 2022 .

Venetoclax-rituximab ± bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma: CONTRALTO.

I. Flinn, W. Hiddemann, P. Zinzani, 2020, Blood.

Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma.

M. Baccarani, S. Fanti, P. Zinzani, 2007, Clinical lymphoma & myeloma.

Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review

P. Zinzani, P. Cortelli, M. Guarino, 2022, Journal of Neurology.

Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients.

F. Cavalli, S. Pileri, M. Federico, 2002, Haematologica.

Time course, clinical pathways, and long‐term hazards risk trends of disease progression in patients with classic mycosis fungoides

P. Zinzani, M. Fimiani, N. Pimpinelli, 2012, Cancer.

FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study.

D. Huglo, S. Fanti, C. Fonti, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Lymphoma: Clinico-Pathological Findings and Outcome + ALK

S. Pileri, C. Wolf‐Peeters, B. Falini, 2010 .

Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group.

F. Cavalli, A. Taghian, G. Pruneri, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas.

S. Pileri, A. Pileri, S. Chimenti, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.

S. Pileri, F. Gherlinzoni, P. Mazza, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early A utologous S tem-Cell T ransplantation V ersus Conventional C hemotherapy a s F ront-Line T herapy i n H igh- Risk, A ggressive N on-Hodgkin's L ymphoma: A n I talian Multicenter R andomized T rial

F. Gherlinzoni, P. Mazza, F. Mandelli, 2003 .

Primary bone lymphoma: experience with 52 patients.

S. Pileri, M. Baccarani, S. Ascani, 2003, Haematologica.

ALK+ lymphoma: clinico-pathological findings and outcome.

S. Pileri, C. Wolf‐Peeters, B. Falini, 1999, Blood.

Lymphoma : Clinico-Pathological Findings and Outcome

S. Pileri, C. Wolf‐Peeters, B. Falini, 1999 .

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma

F. Bosch, L. Gordon, J. Radford, 2020, Clinical Cancer Research.

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.

I. Flinn, S. de Vos, A. Pettitt, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor.

A. Pileri, P. Zinzani, A. Broccoli, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers

S. Pileri, S. Fanti, P. Zinzani, 2012, BMC Cancer.

Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients.

F. Gherlinzoni, G. Frezza, P. Zinzani, 1996, Leukemia & lymphoma.

Hairy cell leukemia: allogeneic transplantation could be an optimal option in selected patients.

P. Zinzani, F. Bonifazi, G. Bandini, 2012, Clinical lymphoma, myeloma & leukemia.

Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.

P. Zinzani, P. Zinzani, G. Marotta, 1999, Haematologica.

Hairy-cell leukemia and alpha-interferon treatment: long-term responders.

P. Zinzani, S. Tura, M. Salvucci, 1997, Haematologica.

High complete remission rate in hairy cell leukemia treated with 2-chlorodeoxyadenosine.

P. Zinzani, P. Zinzani, S. Tura, 1993, Leukemia & lymphoma.

The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30‐year experience

E. Sabattini, P. Zinzani, C. Terragna, 2021, American journal of hematology.

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

W. Wilson, I. Pastan, J. Delgado, 2018, Leukemia.

Brain dysfunction in COVID‐19 and CAR‐T therapy: cytokine storm‐associated encephalopathy

P. Zinzani, P. Cortelli, D. Janigro, 2021, Annals of clinical and translational neurology.

Oral Abstract: MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study

A. Alencar, I. Flinn, P. Zinzani, 2022, Clinical Lymphoma Myeloma and Leukemia.

PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013)

M. Shipp, P. Zinzani, G. Martinelli, 2014 .

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Michael L. Wang, O. Casasnovas, P. Zinzani, 2017, The Lancet.

Is interferon alpha in cutaneous T‐cell lymphoma a treatment of choice?

P. Mazza, F. Mandelli, G. Papa, 1991, British journal of haematology.

Alpha recombinant interferon in the treatment of mycosis fungoides (MF).

F. Gherlinzoni, P. Mazza, P. Zinzani, 1987, Haematologica.

NR1H3 (LXRα) is associated with pro‐inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b‐cell lymphoma

A. López-Guillermo, E. Campo, S. Pileri, 2022, Hematological oncology.

Survival in HIV‐infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study

P. Zinzani, P. Zinzani, D. Caracciolo, 2018, HIV medicine.

Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma

P. Zinzani, M. Cavo, V. Stefoni, 2020, Leukemia & lymphoma.

Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease.

S. Pileri, B. Falini, S. Ascani, 2004, The Lancet. Oncology.

Angioimmunoblastic T-Cell Lymphoma.

P. Zinzani, A. Broccoli, 2017, Hematology/oncology clinics of North America.

Lymphoma and Myeloma of the Sacrum

P. Zinzani, A. Mavrogenis, P. Ruggieri, 2017 .

Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy

M. Ferracin, P. Zinzani, M. Bonafè, 2022, Frontiers in Immunology.

Anaplastic large cell lymphoma (CD30+/Ki‐1+): results of a prospective clinico‐pathological study of 69 cases

S. Pileri, H. Stein, F. Gherlinzoni, 1994, British journal of haematology.

Peripheral T cell lymphomas: from the bench to the clinic

W. Chan, P. Zinzani, G. Inghirami, 2020, Nature Reviews Cancer.

The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma

R. Marcus, P. Zinzani, K. Ardeshna, 2021, Clinical Cancer Research.

Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study

G. Lenz, A. Santoro, A. Nagler, 2019, American journal of hematology.

Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study.

J. Vose, S. Pileri, M. Federico, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients

P. Zinzani, F. Bertoni, C. Tarantelli, 2021, Cancers.

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.

D. Esseltine, S. de Vos, B. Coiffier, 2011, The Lancet. Oncology.

Pyothorax-associated lymphoma: description of the first two cases detected in Italy.

S. Pileri, S. Ascani, P. Zinzani, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

T-Cell Lymphomas in South America and Europe

J. Vose, S. Montoto, J. Connors, 2012, Revista brasileira de hematologia e hemoterapia.

Projeto de célula-T: estudo internacional, longitudinal de pacientes com linfoma de célula-T periférica agressivo

D. Weisenburger, J. Vose, S. Montoto, 2009 .

Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients.

S. Pileri, F. Gherlinzoni, F. Mandelli, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma

S. Pileri, P. Zinzani, G. Martinelli, 2015, Oncotarget.

ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.

N. Schmitz, E. Campo, E. Iannitto, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Clinical activity of everolimus in relapsed/refractory marginal zone B‐cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group

F. Cavalli, G. Gaidano, P. Zinzani, 2014, British journal of haematology.

Fludarabine‐containing chemotherapy as frontline treatment of nongastrointestinal mucosa‐associated lymphoid tissue lymphoma

S. Pileri, M. Baccarani, P. Zinzani, 2004, Cancer.

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

A. Hagenbeek, G. Salles, F. d'Amore, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Peripheral T-cell lymphoma, not otherwise specified.

P. Zinzani, A. Broccoli, 2017, Blood.

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study

R. Greil, G. Salles, P. Zinzani, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non‐Hodgkin B‐cell lymphomas

J. Sancho, P. Zinzani, M. Bregni, 2020, European journal of haematology.

Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience.

P. Zinzani, R. Marasca, C. Visco, 2019, Clinical lymphoma, myeloma & leukemia.

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.

V. Pavone, G. Gaidano, P. Zinzani, 2014, The Lancet. Oncology.

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.

U. Jaeger, S. Kvaløy, M. Pfreundschuh, 2008, The Lancet. Oncology.

Indolent lymphoma: the pathologist's viewpoint.

S. Pileri, A. Pileri, P. Zinzani, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies

J. Burke, J. Vose, J. Gribben, 2017 .

Radioimmunotherapy (RIT) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8‐year follow‐up data of 281 patients from the international RIT‐registry

P. Zinzani, L. Trümper, K. Hohloch, 2018, British journal of haematology.

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

W. Wilson, V. Seshan, R. Advani, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

ADVANCES IN THE TREATMENT OF NON-HODGKIN’S LYMPHOMA: EXPLORING NEW FRONTIERS

E. Kimby, G. Lenz, P. Zinzani, 2016 .

SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma

P. Zinzani, P. Zinzani, G. Barosi, 2013, American journal of hematology.

Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience

M. Baccarani, E. Sabattini, P. Zinzani, 2009, Leukemia & lymphoma.

Hairy cell leukemia variant: a morphologic, immunologic and clinical study of 7 cases.

P. Zinzani, S. Tura, L. Gugliotta, 1990, Haematologica.

Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.

M. Baccarani, P. Zinzani, L. Alinari, 2002, Haematologica.

Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making

M. Gobbi, P. Zinzani, F. Ferrara, 2013, Leukemia.

ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study

R. Greil, G. Salles, P. Zinzani, 2021 .

A RETROSPECTIVE INTERNATIONAL STUDY OF PRIMARY EXTRANODAL MARGINAL ZONE LYMPHOMA OF THE LUNG (BALT-LYMPHOMA)

P. Zinzani, 2007 .

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma

I. Lossos, J. Friedberg, P. Zinzani, 2022, Blood advances.

How do we sequence therapy for marginal zone lymphomas?

P. Zinzani, A. Broccoli, 2020, Hematology. American Society of Hematology. Education Program.

Invited Review: Will Consolidation with ASCT Be a Thing of the Past for MCL and PTCL?

P. Zinzani, A. Broccoli, L. Argnani, 2021, Current Hematologic Malignancy Reports.

Standard of Care in T-Cell Lymphoma

P. Zinzani, D. Chihara, M. Fanale, 2018, essentials.

High-dose therapy and stem cell transplantation.

P. Zinzani, 2010, Seminars in hematology.

Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified.

S. Pileri, M. Baccarani, P. Zinzani, 2005, The Lancet. Oncology.

Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding

G. Boriani, R. Foà, S. Molica, 2018, Hematological oncology.

SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia.

P. Zinzani, G. Meloni, A. Cuneo, 2012, Leukemia research.

Cutaneous adverse‐events in patients treated with Ibrutinib

A. Pileri, P. Zinzani, B. Piraccini, 2020, Dermatologic therapy.

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis

P. Zinzani, S. Horwitz, E. Jacobsen, 2021, Blood.

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

P. Zinzani, D. Cunningham, G. Verhoef, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients.

S. Pileri, M. Baccarani, S. Fanti, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

The role of positron emission tomography (PET) in the management of lymphoma patients.

F. Gherlinzoni, P. Zinzani, P. Zinzani, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Finalization of autologous stem cell transplant in complex and multirelapsed follicular lymphoma

P. Zinzani, M. Cavo, M. Carella, 2020, Tumori.

Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients

M. Baccarani, S. Fanti, P. Zinzani, 2011, European Journal of Nuclear Medicine and Molecular Imaging.

EXABS-224-NQ Next Questions: T-Cell Lymphomas.

P. Zinzani, A. Broccoli, 2022, Clinical lymphoma, myeloma & leukemia.

Cells and Vascular Endothelial Growth Factor Deregulation Lymphoma Indicates Derivation from T Follicular Helper Gene Expression Analysis of Angioimmunoblastic

S. Pileri, S. Ferrari, A. Califano, 2007 .

The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients

P. Zinzani, A. Broccoli, V. Stefoni, 2017, BMC Cancer.

Histopathology of B-cell chronic lymphocytic leukemia.

S. Pileri, T. Marafioti, E. Sabattini, 2004, Hematology/oncology clinics of North America.

Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.

Sun Ku Lee, M. Kersten, B. Cheson, 2019, The Lancet. Haematology.

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper

V. Poletti, P. Zinzani, A. Cuneo, 2018, Hematological oncology.

Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience.

P. Zinzani, A. Broccoli, V. Stefoni, 2021, Journal of clinical medicine.

Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases

E. Sabattini, P. Zinzani, A. Broccoli, 2021, Leukemia & lymphoma.

A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma

A. López-Guillermo, O. Casasnovas, P. Zinzani, 2021, Hematological oncology.

Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi

S. Pileri, L. Ballotta, P. Zinzani, 2021, Frontiers in Oncology.

New target of chronic lymphocytic leukemia treatment.

P. Zinzani, S. Tura, 1994, Haematologica.

Phosphatidyl-inositol 3-kinase inhibitors in the treatment of T-cell lymphomas

P. Zinzani, A. Broccoli, 2018 .

DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE‐REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA

I. Flinn, S. de Vos, A. Pettitt, 2017 .

COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA (CHRONOS‐1)

G. Lenz, A. Santoro, A. Nagler, 2017 .

Phase 1 study of the safety and efficacy of INCB050465 combined with obinutuzumab and bendamustine for relapsed or refractory (R/R) follicular lymphoma (FL) (CITADEL-102).

A. Salar, P. Zinzani, M. Coleman, 2017 .

Phase 2 study of the safety and efficacy of INCB050465 in patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) (CITADEL-202).

P. Zinzani, D. Demarini, V. Ribrag, 2017 .

Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.

R. Fanin, M. Baccarani, F. Mandelli, 2003, Haematologica.

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

A. Zelenetz, P. Abrisqueta, C. Buske, 2019, Blood.

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

M. Grever, A. Saven, B. Falini, 2021, Leukemia.

Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003).

J. Vose, M. Czuczman, P. Zinzani, 2009 .

Cutaneous leukocytoclastic vasculitis in B-cell chronic lymphocytic leukaemia patients.

A. Pileri, P. Zinzani, A. Patrizi, 2019, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.

Expression of platelet-derived growth factor receptor α in peripheral T-cell lymphoma not otherwise specified

S. Pileri, M. Baccarani, P. Zinzani, 2005 .

Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas

S. Serrano, S. Pileri, A. Califano, 2008, Haematologica.

PET/CT in Non-Hodgkin Lymphoma: An Update.

C. Nanni, S. Fanti, P. Zinzani, 2022, Seminars in nuclear medicine.

High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experience.

S. Pileri, F. Gherlinzoni, M. Baccarani, 2003, Haematologica.

Primary ocular adnexal lymphomas: a retrospective study of 25 patients

P. Zinzani, E. Polito, L. Argnani, 2013, Leukemia & lymphoma.

Lymphohematopoietic Malignancies

A. Farioli, F. Violante, P. Zinzani, 2020, Occupational Cancers.

Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma

P. Zinzani, T. Illidge, N. Rezaei, 2019, International reviews of immunology.

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

M. Kersten, P. Zinzani, M. Subklewe, 2021, Blood advances.

Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

J. Radford, P. Zinzani, K. Ardeshna, 2020 .

Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients.

M. Gobbi, F. Gherlinzoni, P. Mazza, 1999, Blood.

Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma.

M. Gobbi, F. Gherlinzoni, B. Falini, 1997, Blood.

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma

G. Salles, G. Fingerle-Rowson, P. Zinzani, 2021, Clinical Cancer Research.

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma

Matthew J. Frigault, R. Houot, V. Torri, 2021, Leukemia.

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.

I. Flinn, P. Zinzani, A. Howes, 2022, The New England journal of medicine.

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

A. Alencar, A. Zelenetz, I. Flinn, 2022, Blood.

Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.

T. Lister, F. Morschhauser, P. Zinzani, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical implications of cytokine and soluble receptor measurements in patients with newly‐diagnosed aggressive non‐Hodgkin's lymphoma

P. Galieni, G. Papa, P. Zinzani, 1995, European journal of haematology.

Results of a fludarabine induction and α‐interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low‐grade non‐Hodgkin's lymphoma

P. Zinzani, E. Zamagni, S. Tura, 1997, European journal of haematology.

Hodgkin's disease (HD): A historical perspective☆

M. Gobbi, F. Gherlinzoni, P. Mazza, 1986 .

Corrigendum: Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue (Annals of Oncology (2018) 29 (2363-2370) DOI: 10.1093/annonc/mdy450)

A. López-Guillermo, E. Campo, S. Pileri, 2019 .

Long-term follow-up after fludarabine treatment in pretreated patients with chronic lymphocytic leukemia.

P. Zinzani, S. Tura, D. Rondelli, 2000, Haematologica.

Critical value of laparotomy with splenectomy in Stage III Hodgkin's disease as restaging procedure after chemotherapy

F. Gherlinzoni, P. Mazza, P. Zinzani, 1988, European journal of haematology.

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy

F. Gherlinzoni, P. Zinzani, C. Minoia, 2022, HemaSphere.

Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).

R. Advani, A. Hagenbeek, G. Salles, 2014 .

Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study

P. Zinzani, N. Bartlett, J. Kuruvilla, 2022, Leukemia & lymphoma.

Lymph node core needle biopsy in lymphoproliferative disorders—Authors’ reply to Al‐Abbadi and colleagues

E. Sabattini, P. Zinzani, A. D. Dei Tos, 2021, European journal of haematology.

Lymph node core needle biopsy for the diagnosis of lymphoproliferative disorders: A word of caution

E. Sabattini, P. Zinzani, A. D. Dei Tos, 2021, European Journal of Haematology.

Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma

C. Nanni, S. Fanti, E. Sabattini, 2020, European Journal of Nuclear Medicine and Molecular Imaging.

A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report.

M. Federico, P. Zinzani, F. Merli, 2014 .

Primary cutaneous B‐cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers

S. Ascani, P. Zinzani, M. Paulli, 2016, Cancer medicine.

Plaques and tumors in a patient with refractory Sézary syndrome treated with mogamulizumab

A. Pileri, E. Sabattini, P. Zinzani, 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Erythroderma with brentuximab vedotin (skin side effects in mycosis fungoides)

A. Pileri, P. Zinzani, C. Agostinelli, 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

C. Elmets, R. Dummer, R. Cowan, 2019, Blood.

Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.

M. Dimopoulos, C. Buske, P. Zinzani, 2020, Blood advances.

A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia

P. Zinzani, D. Catovsky, C. Dearden, 2022, Blood advances.

Risk of second cancer in patients with hairy cell leukemia: long-term follow-up.

M. Vinceti, T. Chisesi, M. Federico, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW‐UP OF THE PHASE 2 CHECKMATE 205 TRIAL

K. Savage, M. Shipp, K. Kato, 2017 .

Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma.

M. Gobbi, F. Gherlinzoni, P. Mazza, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy.

P. Zinzani, M. Carella, A. Broccoli, 2021, Clinical Lymphoma, Myeloma & Leukemia.

Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study

R. Foà, S. Molica, M. Vignetti, 2016 .

Cryptococcal meningitis and intracranial tuberculoma in a patient with Waldenstrom's macroglobulinemia treated with fludarabine.

P. Zinzani, R. Luzzati, E. Aitini, 1998, Leukemia & lymphoma.

Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM).

M. Kersten, P. Zinzani, E. Kastritis, 2018 .

Leukocytoclastic Vasculitis Associated with Hairy Cell Leukemia at Diagnosis: A Case Report and Review of the Literature

P. Zinzani, C. Agostinelli, A. Broccoli, 2016, Tumori.

High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.

F. Gherlinzoni, M. Vignetti, F. Mandelli, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas.

S. Pileri, F. Gherlinzoni, P. Zinzani, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II-IV diffuse non-Hodgkin's lymphomas.

F. Gherlinzoni, P. Mazza, P. Zinzani, 1989, Haematologica.

Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients.

S. Pileri, F. Gherlinzoni, S. Ascani, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy

M. Baccarani, P. Zinzani, L. Alinari, 2005, Leukemia & lymphoma.

Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients.

F. Gherlinzoni, P. Mazza, M. Baccarani, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

M. Grever, A. Saven, B. Falini, 2022, Blood cancer journal.

Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas

F. Gherlinzoni, P. Galieni, P. Mazza, 2004, Cancer Chemotherapy and Pharmacology.

Effects of a new bifunctional alkylating agent (PTT-119) on in vitro growth of human cell lines and normal myeloid progenitors (CFU-GM).

F. Gherlinzoni, P. Mazza, P. Zinzani, 1988, Haematologica.

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

G. Mulligan, D. Esseltine, S. de Vos, 2013, Clinical Cancer Research.

Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin’s lymphoma patients

M. Gobbi, E. Iannitto, G. Gaidano, 2012, Annals of Hematology.

Expert Consensus on the Characteristics of Patients with Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study

E. González-Barca, P. Zinzani, S. Schneeberger, 2023, Advances in Therapy.

T‐Cell Lymphoproliferative Disorders

P. Zinzani, A. Broccoli, 2015 .

Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study

M. Shipp, N. Johnson, J. Radford, 2016 .

New therapies and old side‐effects in mycosis fungoides treatment: brentuximab vedotin‐induced alopecia

A. Pileri, P. Zinzani, B. Piraccini, 2019, The British journal of dermatology.

Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial

J. Scarisbrick, P. Zinzani, L. Iversen, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study

C. Elmets, J. Scarisbrick, P. Zinzani, 2017 .

Granulocyte colony stimulating factor (G-CSF) as adjunct therapy in relapsed-resistant high-grade non-Hodgkin's lymphoma.

F. Mandelli, P. Zinzani, P. Zinzani, 1993, Haematologica.

Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

M. Weichenthal, R. Dummer, O. Akilov, 2021, European journal of cancer.

Traditional Treatment Approaches in B-cell Non-Hodgkin's Lymphoma

P. Zinzani, 2003, Leukemia & lymphoma.

Gene Expression Analysis of Peripheral T-Cell Lymphoma Not Otherwise Specified Reveals the Existance of Two Subgroups Related to Different Cellular Counterparts and Recurrent PDGFRA Deregulation.

K. Basso, S. Pileri, A. Califano, 2005 .

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

K. Savage, P. Zinzani, S. Horwitz, 2022, Blood advances.

Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients

M. Baccarani, C. Nanni, S. Fanti, 2004, British Journal of Cancer.

THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE‐2 TRIAL

R. Foà, B. Falini, G. Gaidano, 2019, Hematological Oncology.

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

P. Zinzani, K. Ardeshna, S. Opat, 2022, Blood.

Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial.

C. Flowers, P. Ganly, P. Zinzani, 2022, Journal of Clinical Oncology.

90‐yttrium‐ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high‐risk follicular lymphoma: updated long‐term results after a median follow‐up of 7 years

P. Zinzani, A. Pulsoni, A. De Renzo, 2016, Cancer medicine.

A Phase II Trial of FM (Oral Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Follicular Lymphoma (FL) Patients.

M. Voso, S. Fanti, P. Zinzani, 2005 .

Adult Burkitt's lymphoma: clinical and prognostic evaluation of 20 patients.

F. Gherlinzoni, P. Zinzani, S. Tura, 1994, Leukemia & lymphoma.

Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience

B. Falini, L. Pagano, P. Zinzani, 2020 .

Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study

B. Falini, L. Pagano, P. Zinzani, 2022, Blood Cancer Journal.

Is it really possible to cure hairy cell leukemia patients only with frontline therapy?

S. Pileri, P. Zinzani, R. Maglie, 2014, Annals of Hematology.

Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients

P. Zinzani, E. Derenzini, M. Ladetto, 2015 .

Primary gastric diffuse large-cell lymphoma.

P. Zinzani, 2006, Leukemia & lymphoma.

Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study

C. Buske, G. Gaidano, P. Zinzani, 2016 .

Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.

R. Fanin, F. Mandelli, P. Zinzani, 1994, Haematologica.

Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.

S. Pileri, M. Baccarani, B. Falini, 2005, Haematologica.

Serum soluble interleukin-2 receptor levels in hairy cell leukemia: correlation with clinical and hematological parameters and with alpha-interferon treatment.

S. Pileri, E. Sabattini, P. Zinzani, 1992, Leukemia & lymphoma.

Safety of third dose of COVID-19 vaccination in frail patients: Results from the prospective Italian VAX4FRAIL study

G. Ciliberto, F. Baldanti, G. Apolone, 2022, Frontiers in Oncology.

mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients

G. Ciliberto, F. Baldanti, G. Apolone, 2022, Frontiers in Oncology.

Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study

G. Ciliberto, F. Baldanti, G. Apolone, 2022, medRxiv.

COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial

G. Ciliberto, F. Baldanti, G. Apolone, 2021, Frontiers in Immunology.

CDKN1B/ p27 expression in peripheral T cell lymphoma not otherwise speciﬁed

S. Pileri, E. Sabattini, P. Zinzani, 2022 .

Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma

S. Pileri, P. Pelicci, P. Zinzani, 2021, Leukemia.

Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi

V. Pavone, G. Gaidano, P. Zinzani, 2013 .

Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia: a new treatment schedule effective and safer in preventing infectious complications.

P. Zinzani, P. Zinzani, G. Marotta, 1997, Blood.

Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up

M. Vinceti, T. Chisesi, M. Federico, 2002 .

Long-term follow-up studies in hairy cell leukemia

M. Grever, P. Zinzani, 2009, Leukemia & lymphoma.

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma.

F. Cavalli, P. Zinzani, F. Merli, 2015, Blood.

Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue

A. López-Guillermo, E. Campo, S. Pileri, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Idelalisib as a Bridge to Allogeneic Transplantation in Relapsed/Refractory Lymphoma With Renal Cancer: A Case Report.

P. Zinzani, M. Cavo, A. Broccoli, 2019, Clinical lymphoma, myeloma & leukemia.

Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial

G. Salles, M. Shipp, P. Zinzani, 2017 .

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

M. Kersten, P. Riedell, R. Malladi, 2020, Transplantation and Cellular Therapy.

The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial

P. Zinzani, O. O’Connor, Sung-Soo Yoon, 2021, Blood.

Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial

J. Burke, J. Reeves, B. Cheson, 2020 .

Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis

I. Lossos, J. Friedberg, P. Zinzani, 2020 .

Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study

F. D'Alo', P. Zinzani, A. Cuneo, 2022, Cancers.

Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B‐cell lymphoma in the phase III clinical trial of R‐CHOP ± ibrutinib

L. Staudt, W. Wilson, L. Sehn, 2021, British journal of haematology.

Real‐world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR‐2 retrospective chart review study

E. Giné, J. Sancho, P. Zinzani, 2022, British journal of haematology.

Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations

P. Zinzani, M. Jerkeman, M. Dreyling, 2018, Leukemia & lymphoma.

Relationship between immunological phenotype and hematological response to α‐IFN treatment in 35 patients with hairy cell leukemia

R. Foà, P. Zinzani, S. Tura, 1990, European journal of haematology. Supplementum.

Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma

L. Rimsza, P. Zinzani, T. Witzig, 2019, Blood Cancer Journal.

The Small Molecule CHK1/CHK2 Inhibitor PF-0477736 (Pfizer) Demonstrates Single Agent Activity and Synergizes with Chemotherapy in Diffuse Large B-Cell Lymphoma

S. Pileri, M. Baccarani, P. Zinzani, 2011 .

The Small Molecule JAK1/JAK2 Inhibitor INCB16562 Shows Single Agent Activity and Strongly Synergizes with Bcl-2 Inhibitors in Lymphoma

P. Zinzani, A. Younes, M. Lemoine, 2011 .

A three-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma

S. Pileri, G. Pruneri, E. Sabattini, 2020, Haematologica.

Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL)

V. Pavone, G. Gaidano, P. Zinzani, 2012 .

FDG-PET in the serial assessment of patients with lymphoma in complete remission

V. Ambrosini, C. Nanni, D. Rubello, 2007 .

To what extent can indolent lymphoma be considered? Results of a long term follow-up study from a single center.

F. Gherlinzoni, P. Zinzani, S. Tura, 1998, Haematologica.

A treatment for activated B-cell-like DLBCL?

P. Zinzani, 2014, The Lancet. Oncology.

Immunophenotype and intermediate‐high international prognostic index score are prognostic factors for therapy in diffuse large B‐cell lymphoma patients

S. Pileri, M. Baccarani, P. Zinzani, 2010, Cancer.

Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

Ryan D. Morin, S. Pileri, R. Morin, 2018, Leukemia & lymphoma.

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.

N. Johnson, P. Zinzani, J. Kuruvilla, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma

P. Zinzani, K. Ardeshna, F. Morschhauser, 2019, Leukemia & lymphoma.

PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and Biomarker Assessment

M. Shipp, P. Zinzani, P. Armand, 2015 .

Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.

P. Zinzani, R. Marasca, C. Visco, 2019, The oncologist.

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

M. Kersten, P. Riedell, R. Malladi, 2021, Blood.

CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission

P. Zinzani, E. Derenzini, A. Broccoli, 2009, Journal of Neuro-Oncology.

Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab

P. Zinzani, A. Broccoli, C. Pellegrini, 2016, Haematologica.

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)

F. Bosch, L. Gordon, J. Radford, 2023, Oncotarget.

Management of central nervous system relapse in a young patient affected by primary mediastinal large B‐cell lymphoma: A case report

P. Zinzani, M. Cavo, A. Broccoli, 2020, Clinical case reports.

Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma.

P. Zinzani, M. Gospodarowicz, D. Cunningham, 2017, International journal of radiation oncology, biology, physics.

The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B‐cell lymphoma: experience on 74 patients

S. Pileri, S. Fanti, P. Zinzani, 2015, Hematological oncology.

Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma.

S. Pileri, M. Baccarani, R. Trisolini, 2007, Haematologica.

Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters

G. Ciliberto, F. Baldanti, G. Apolone, 2022, Frontiers in Immunology.

Midtreatment 18F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

M. Baccarani, S. Fanti, P. Zinzani, 2011, Cancer.

The many faces of marginal zone lymphoma.

P. Zinzani, 2012, Hematology. American Society of Hematology. Education Program.

Prolonged bone marrow aplasia of refractory porolymphocytoid variant of B‐cell chronic lymphocytic leukemia related to fludarabine treatment

P. Zinzani, S. Tura, M. Bendandi, 1994, European journal of haematology.

Multi-centre, phase II study of combination antibody therapy with epratuzumab plus rituximab in relapsed/refractory indolent and aggressive NHL: Promising preliminary results.

T. Lister, P. Zinzani, S. Strauss, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Mantle-Cell Lymphoma: Results of An International Study (NHL-003)

J. Vose, M. Czuczman, R. Bouabdallah, 2008 .

Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients

P. Zinzani, M. Cavo, M. Carella, 2020, Annals of Hematology.

Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.

F. Gherlinzoni, G. Frezza, S. Fanti, 1996, Leukemia & lymphoma.

Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.

R. Foà, B. Falini, G. Gaidano, 2021, The New England journal of medicine.

FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.

P. Zinzani, G. Martinelli, S. Tura, 1996, Leukemia & lymphoma.

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial.

P. Zinzani, A. Di Rocco, A. Chiappella, 2017, Blood.

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results

P. Zinzani, S. Horwitz, S. Lustgarten, 2020 .

A Multi-Center Phase II Study (SAKK 36/06) of Single Agent Everolimus (RAD001) In Patients with Relapsed or Refractory Mantle Cell Lymphoma.

P. Zinzani, G. Martinelli, S. Cogliatti, 2010 .

SAFETY AND EFFICACY OF 90 Y IBRITUMUMAB TIUXETAN (ZEVALIN) FOR UNTREATED FOLLICULAR NON HODGKIN'S LYMPHOMA (FL) PATIENTS. ITALIAN MULTICENTRIC TRIAL.

P. Zinzani, A. Carella, U. Vitolo, 2011 .

Role of interferon‐alpha administration after 2‐deoxycoformycin in the treatment of hairy cell leukemia patients

R. Foà, M. Federico, P. Zinzani, 2006, European journal of haematology.

Clinicopathological study on non-Hodgkin's lymphomas.

S. Pileri, F. Gherlinzoni, P. Mazza, 1987, Haematologica.

Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients.

F. Gherlinzoni, P. Zinzani, S. Tura, 1999, Haematologica.

The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium

J. Friedberg, K. Savage, A. Rodday, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma.

F. Cavalli, L. Cascione, P. Zinzani, 2018, Blood.

PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B12 and Folic Acid Supplementation in Patients with Replapsed or Refractory Peripheral T-Cell Lymphoma

K. Savage, B. Coiffier, P. Zinzani, 2008 .

Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)

M. Shipp, N. Johnson, J. Radford, 2021, Blood.

Critical Role of Hodgkin Lymphoma Cells-Derived Large and Small Extracellular Vesicles in the Regulation of the Immune-Inflammatory Microenvironment

P. Zinzani, A. Budillon, D. Forte, 2022, Blood.

Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Long-Term Efficacy from the Phase 1b Keynote-013 Study

M. Shipp, P. Zinzani, P. Armand, 2016 .

Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.

A. Levis, V. Pavone, G. Gaidano, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

L. Staudt, W. Wilson, J. Vose, 2019, Blood.

Ki-1 lymphoma and Hodgkin's disease.

S. Pileri, P. Mazza, B. Falini, 1989, Haematologica.

Development of a distributed international patient data registry for hairy cell leukemia

M. Grever, A. Saven, P. Zinzani, 2022, Leukemia & lymphoma.

Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind

G. Salles, E. González-Barca, G. Gaidano, 2018, Blood.

Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

R. Advani, A. Hagenbeek, G. Salles, 2014 .

ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

J. Radford, P. Zinzani, K. Ardeshna, 2021 .

PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE‐087 STUDY

M. Shipp, J. Radford, P. Zinzani, 2017 .

Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

M. Shipp, N. Johnson, J. Radford, 2018, Blood.

A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report

P. Zinzani, C. Agostinelli, M. Cavo, 2018, BMC Cancer.

The Role of Interim-PET and Final-PET in the Outcome of Peripheral T-Cell Lymphoma (PTCL) Treated At the Diagnosis with CHOP.

P. Zinzani, E. Derenzini, A. Broccoli, 2012 .

Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report

P. Zinzani, M. Cavo, M. Gentilini, 2020, Acta Haematologica.

Effectiveness and Safety of Pixantrone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Every-Day Clinical Practice: The Italian Cohort of the PIXA Registry

P. Zinzani, M. Bregni, A. Pinto, 2020, Acta Haematologica.

Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma: post‐hoc analyses from a phase III trial

B. Coiffier, P. Zinzani, C. Sebban, 2016, British journal of haematology.

Impressive Response to Pixantrone after Allogeneic Transplant in a Multiple Relapsed Diffuse Large B-Cell Lymphoma

P. Zinzani, B. Casadei, C. Pellegrini, 2017, Acta Haematologica.

The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients

P. Zinzani, A. Broccoli, V. Stefoni, 2017, BMC Cancer.

Discovery of Candidate Predictors of Response to Tazemetostat in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Using NGS Technology on ctDNA Samples Collected Pre-Treatment

G. Salles, R. Morin, J. Radford, 2017 .

Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature

P. Zinzani, C. Agostinelli, A. Broccoli, 2012, Rheumatology International.

ROCHOP study: A phase III randomized study of CHOP compared to romidepsin-CHOP in untreated peripheral T-cell lymphoma.

P. Gaulard, B. Coiffier, P. Zinzani, 2013 .

PI3K inhibitors in haematological malignancies.

P. Zinzani, B. Childs, M. Matasar, 2022, The Lancet. Oncology.

Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: Results from an international study (NHL-003).

J. Vose, M. Czuczman, R. Bouabdallah, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Mantle Cell Lymphoma Previously Treated with Bortezomib: Pooled Data from Two Phase II Studies (NHL-002 and NHL-003).

J. Vose, M. Czuczman, R. Bouabdallah, 2008 .

Recombinant alpha-2a interferon in HIV-associated myelodysplasia.

F. Gherlinzoni, P. Mazza, P. Zinzani, 1988 .

Phase II Study of Proteasome Inhibitor Bortezomib (Velcade®) in Patients with Relapsed/Refractory T-Cell Lymphoma: Preliminary Results.

M. Baccarani, P. Zinzani, E. Marchi, 2006 .

A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

L. Staudt, W. Wilson, L. Sehn, 2018, Blood.

Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment: An open-label phase 1/2 study.

N. Johnson, P. Zinzani, A. Bazargan, 2022, Journal of Clinical Oncology.

The Integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).

P. Zinzani, C. Deng, O. O’Connor, 2020 .

A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).

L. Staudt, W. Wilson, R. Gascoyne, 2014 .

MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients

H. Stein, F. Angrilli, K. Naresh, 2018, Haematologica.

High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience

P. Zinzani, E. Derenzini, A. Broccoli, 2015, BMC Cancer.

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial

N. Johnson, A. Santoro, P. Zinzani, 2018, Blood.

Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies

G. Salles, D. Neuberg, M. Shipp, 2018, Blood.

Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study.

R. Dummer, P. Zinzani, K. Wood, 2017 .

Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine+Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data

P. Zinzani, M. Crump, I. Fleury, 2016 .

A Phase 1B Study of CC-122 in Combination with Obinutuzumab (GA101) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin Lymphoma

M. Kersten, R. Bouabdallah, P. Zinzani, 2016 .

CD30+ expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project.

R. Advani, J. Vose, S. Montoto, 2015 .

Hodgkin's disease: controversies and challenges for the future.

P. Zinzani, W. Urba, S. Tura, 1991, Haematologica.

Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study.

M. Shipp, N. Johnson, J. Radford, 2016 .

Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)--A phase 2 study.

K. Savage, M. Shipp, A. Santoro, 2016 .

Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

K. Savage, M. Shipp, A. Santoro, 2018, Blood.

Emerging role of GSK-3 β in the pathobiology of classical Hodgkin Lymphoma Running title : GSK-3 β in classical Hodgkin Lymphoma

S. Pileri, P. Zinzani, M. Fiorentino, 2017 .

New Agents in Marginal Zone Lymphomas

P. Zinzani, A. Broccoli, 2021 .

Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

P. Zinzani, P. Lugtenburg, S. Y. Kim, 2021 .

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma

M. Millenson, A. Santoro, P. Zinzani, 2016 .

A Randomized Trial of Fludarabine and Mitoxantrone Plus Rituximab vs CHOP Plus Rituximab as First-Line Treatment in Patients With Follicular Lymphoma

P. Zinzani, 2002 .

Moxetumomab pasudotox in heavily pretreated patients with relapsed/refractory hairy cell leukemia: Results of a pivotal international study.

W. Wilson, I. Pastan, J. Delgado, 2018 .

Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma

I. Flinn, A. Pettitt, Weiliang Shi, 2016 .

Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)

M. Weichenthal, R. Dummer, O. Akilov, 2017 .

Role of Anemia in Survival of Elderly Aggressive Non-Hodgkin’s Lymphoma Patients Following Chemotherapy.

M. Baccarani, P. Zinzani, L. Alinari, 2004 .

Lenalidomide in Combination with Bendamustine for Patients with Chemorefractory Hodgkin Lymphoma: Final Results of the Leben Multicenter Phase 1/2 Study

F. Angrilli, V. Pavone, P. Zinzani, 2015 .

Idarubicin in low-grade non-Hodgkin's lymphomas.

P. Zinzani, 1997, Haematologica.

FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin's lymphoma.

F. Gherlinzoni, P. Zinzani, S. Tura, 1996, Haematologica.

Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: A diagnostic and therapeutic challenge

M. Baccarani, P. Zinzani, S. Paolini, 2008, Leukemia & lymphoma.

High-Dose Therapy with Autologous Transplantation for Aggressive Non-Hodgkin's Lymphoma: The Bologna Experience

S. Pileri, F. Gherlinzoni, M. Baccarani, 2004, Leukemia & lymphoma.

Hodgkin's disease: summary of twenty years' experience.

F. Gherlinzoni, G. Frezza, P. Mazza, 1992, Haematologica.

Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies

S. Pileri, B. Falini, P. Zinzani, 2008, Journal of Clinical Pathology.

Peripheral T-cell lymphoma.

J. Vose, R. Gascoyne, P. Zinzani, 2011, Blood.

Understanding the group of peripheral T-cell lymphomas, unspecified.

P. Zinzani, E. Zucca, 2005, Current hematology reports.

HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL).

R. Advani, K. Savage, J. Radford, 2022, Clinical Lymphoma, Myeloma & Leukemia.

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)

Wei Jiang, P. Venugopal, P. Zinzani, 2020 .

Gastric MALT Lymphoma in a Sleeve Gastrectomy Specimen: Case Report and Literature Review

E. Sabattini, P. Zinzani, C. Agostinelli, 2018, Bariatric Surgical Practice and Patient Care.

HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

K. Savage, U. Jaeger, M. Shipp, 2021 .

"Very late" relapses in Hodgkin's disease patients: a rare but real phenomenon.

F. Gherlinzoni, P. Mazza, P. Zinzani, 1992, Haematologica.

EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME

P. Zinzani, A. Frustaci, M. Deodato, 2023, Hematological Oncology.

Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib

G. Salles, A. Santoro, G. Follows, 2017 .

Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study

J. Gribben, G. Salles, J. Radford, 2018, Blood.

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)

Wei Jiang, G. Salles, J. Sancho, 2020, Blood.

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

A. Alencar, I. Flinn, P. Zinzani, 2022, Blood.

18F-FDG small animal PET for early detection of human anaplastic large cells lymphoma xenograft in immunocompromised mice.

V. Ambrosini, C. Nanni, D. Rubello, 2008, Anticancer research.

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

R. Advani, K. Savage, P. Zinzani, 2019, Blood.

A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies

P. Zinzani, M. Cavo, A. Broccoli, 2019, Hematological oncology.

Thoughts on the eradication of Helicobacter pylori infection in localized gastric mucosa-associated lymphoid tissue lymphoma

P. Zinzani, 2006, Leukemia & lymphoma.

Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial

S. Pileri, R. Foà, B. Falini, 2014 .

Abstract CT106: Anti-LAG-3 antibody MK-4280 in combination with pembrolizumab for the treatment of hematologic malignancies: A Phase I/II study

P. Zinzani, P. Armand, J. Palcza, 2019, Clinical Trials.

The Chemotherapy-Free Combination of Vemurafenib and Rituximab Produces Deep and Durable Responses in Relapsed or Refractory Hairy Cell Leukemia (HCL) Patients

R. Foà, B. Falini, G. Gaidano, 2017 .

Intensive Chemotherapy Regimen in High-Grade non Hodgkin's Lymphomas

F. Gherlinzoni, P. Mazza, P. Zinzani, 1987, Tumori.

How do patients with aggressive non-Hodgkin’s lymphoma treated with third-generation regimens fare in the long-term?

M. Gobbi, F. Gherlinzoni, F. Mandelli, 1999 .

Massive Mediastinal Involvement in 1-11 Hodgkin's Disease : Response Combined Modality Treatment Stage to

F. Gherlinzoni, G. Frezza, P. Mazza, 1992 .

Re-evaluation of prognosis in stages I and II Hodgkin's disease with bulky mediastinal involvement.

F. Gherlinzoni, P. Mazza, P. Zinzani, 1987, Haematologica.

Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 Study

Michael L. Wang, P. Zinzani, E. Jacobsen, 2017 .

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

R. Advani, K. Savage, P. Zinzani, 2020 .

Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

A. Zelenetz, P. Zinzani, T. Phillips, 2022, Blood.

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)

I. Lossos, P. Zinzani, T. Phillips, 2021, Blood.

CLINICAL ACTIVITY OF LONCASTUXIMAB TESIRINE PLUS IBRUTINIB IN NON‐HODGKIN LYMPHOMA: UPDATED LOTIS 3 PHASE 1 RESULTS

P. Zinzani, T. Phillips, K. Havenith, 2021, Hematological Oncology.

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

J. Radford, P. Zinzani, A. Stathis, 2019, Blood.

Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib within a Named Patient Program (NPP) in Italy. a Real-Life Retrospective Study

R. Foà, M. Gobbi, S. Molica, 2018, Blood.

CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)

K. Savage, J. Radford, S. Ansell, 2021, Hematological Oncology.

A PHASE 2 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE (LONCA) VERSUS (VS) IDELALISIB IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) – LOTIS‐6

P. Zinzani, K. Ardeshna, C. Carlo-Stella, 2021, Hematological Oncology.

NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDY

N. Johnson, A. Santoro, P. Zinzani, 2021, Hematological Oncology.

Planned Interim Analysis of a Phase 2 Study of Loncastuximab Tesirine Plus Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma (LOTIS-3)

P. Zinzani, C. Carlo-Stella, A. Ervin‐Haynes, 2021, Blood.

Efficacy and Safety of Pembrolizumab in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMBCL): Updated Analysis of the Keynote-170 Phase 2 Trial

G. Salles, M. Shipp, P. Zinzani, 2017 .

Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylosoxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG

D. Weisenburger, J. Armitage, F. Cavalli, 2011 .

Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial

M. Shipp, P. Zinzani, P. Armand, 2016 .

Clinical Response in Heavily Pretreated Mycosis Fungoides with Pembrolizumab: A Case Report

A. Pileri, P. Zinzani, B. Casadei, 2021, Acta Haematologica.

Impressive Continuous Complete Response after Mogamulizumab in a Heavily Pretreated Sézary Syndrome Patient

P. Zinzani, M. Cavo, B. Casadei, 2020, Mediterranean Journal of Hematology and Infectious Diseases.

a Phase Iia Study Of Single-agent Mor208, An Fc-optimized Anti-cd19 Antibody, In Patients With Relapsed Or Refractory B-cell Non-hodgkin's Lymphoma : 140

C. Buske, P. Zinzani, M. Winderlich, 2015 .

Phase IIa study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL).

C. Buske, P. Zinzani, M. Winderlich, 2015 .

A phase 1/2 study of lenalidomide and bendamustine (LEBEN) in chemorefractory Hodgkin lymphoma.

F. Angrilli, V. Pavone, P. Zinzani, 2014 .

The Follicular Lymphoma International Prognostic Index (FLIPI) Can Be a Useful Prognostic Indicator for Patients with Follicular Lymphoma Treated with Combination of Rituximab and Epratuzumab.

B. Coiffier, T. Lister, P. Zinzani, 2005 .

Ultrasound-guided core-needle biopsy is effective in the initial diagnosis of lymphoma patients.

S. Pileri, F. Gherlinzoni, S. Ascani, 1998, Haematologica.

Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma

L. Rimsza, P. Zinzani, T. Witzig, 2019, Blood Cancer Journal.

Phase II study with a new alkylating agent (PTT-119) in lymphoid malignancies.

F. Gherlinzoni, P. Galieni, P. Mazza, 1988, Haematologica.

Reactive follicular lymphoid infiltrate: A new condition to exclude in patients with PET positivity inside the heart

C. Nanni, C. Rapezzi, P. Zinzani, 2014, Journal of Nuclear Cardiology.

Peripheral T cell lymphomas: from the bench to the clinic

W. Chan, P. Zinzani, G. Inghirami, 2020, Nature Reviews Cancer.

T-Cell and B-Cell Non-Hodgkin ’ s Lymphoma Revisited : Therapeutic Paradigms and Advances 1 Introduction

R. Gascoyne, P. Zinzani, S. Rosen, 2009 .

Weekly Infusion of Bortezomib In Combination with Rituximab In Relapsed/Refractory Indolent Non-Follicular and Mantle Cell Lymphoma Is Safe and Effective: Two-Years Analysis of Phase II Trial BRIL06 of Intergruppo Italiano Linfomi (IIL)

P. Zinzani, S. Franceschetti, F. Facchetti, 2010 .

The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL)

P. Zinzani, S. Franceschetti, M. Martelli, 2015 .

The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B‐cell lymphoma: experience on 74 patients

S. Pileri, S. Fanti, P. Zinzani, 2015, Hematological oncology.

Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome.

S. Pileri, M. Baccarani, S. Fanti, 2010, Clinical Lymphoma, Myeloma & Leukemia.

Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.

A. López-Guillermo, E. Campo, F. Cavalli, 2003, Blood.

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.

R. Foà, D. Rossi, G. Gaidano, 2015, Blood.

P. Zinzani, G. Barosi, S. Tura, 2005, Haematologica.

Chlorambucil plus rituximab with or without maintenance rituximab as first‐line treatment for elderly chronic lymphocytic leukemia patients

R. Foà, S. Molica, S. Chiaretti, 2014, American journal of hematology.

Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.

B. Coiffier, F. d'Amore, M. Federico, 2014, Cancer treatment reviews.

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

M. Shipp, N. Johnson, J. Radford, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PET/CT in lymphoma staging? On the road to a new gold standard

P. Zinzani, M. Zompatori, A. Poerio, 2018 .

Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma.

S. Fanti, P. Zinzani, E. Derenzini, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

C. Elmets, J. Scarisbrick, P. Zinzani, 2018, The Lancet. Oncology.

A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium‐90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non‐Hodgkin lymphoma

M. Baccarani, S. Fanti, P. Zinzani, 2008, Cancer.

F. Angrilli, S. Molica, P. Zinzani, 2016, European journal of cancer.

U. Jaeger, S. Kvaløy, M. Pfreundschuh, 2008, The Lancet. Oncology.

Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin's Lymphoma (EXTEND): Results From the Treatment and Follow-up Periods.

B. Coiffier, H. Gómez, P. Zinzani, 2009 .

Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports.

P. Zinzani, E. Derenzini, A. Broccoli, 2013, Clinical Lymphoma, Myeloma & Leukemia.

Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma.

S. Pileri, M. Baccarani, P. Zinzani, 2005, Haematologica.

ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY

O. Casasnovas, P. Zinzani, P. Jain, 2021, Hematological Oncology.

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

G. Mulligan, D. Esseltine, S. de Vos, 2013, Clinical Cancer Research.

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study

Michael L. Wang, P. Zinzani, P. Jain, 2020, Blood.

Possible novel agents in marginal zone lymphoma.

P. Zinzani, A. Broccoli, 2017, Best practice & research. Clinical haematology.

Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin’s lymphoma patients

M. Gobbi, E. Iannitto, G. Gaidano, 2012, Annals of Hematology.

Efficacy of Idelalisib as Bridge to Allogeneic Stem Cell Transplant in Relapsed Follicular Lymphoma: A Case Report

P. Zinzani, C. Pellegrini, L. Argnani, 2017, Tumori.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

K. Savage, Y. Oki, J. Radford, 2018, The New England journal of medicine.

Safety and Efficacy of Allogeneic Hematopoetic Stem Cell Transplant (HSCT) after Treatment with Programmed Cell Death 1 (PD-1) Inhibitors

J. Ritz, M. Perales, P. Zinzani, 2015 .

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma.

F. Cavalli, P. Zinzani, F. Merli, 2015, Blood.

K. Savage, M. Shipp, A. Santoro, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

B. Coiffier, H. Gómez, P. Zinzani, 2012, The Lancet. Oncology.

A Phase II Trial of R-FM (Rituximab, Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan ( 90 Y-IT) for Untreated Follicular Lymphoma (FL) Patients.

M. Baccarani, S. Fanti, P. Zinzani, 2009 .

Angioimmunoblastic T-Cell Lymphoma.

P. Zinzani, A. Broccoli, 2017, Hematology/oncology clinics of North America.

EFFICACY AND SAFETY IN HIGH‐RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB

G. Lenz, A. Santoro, A. Nagler, 2019, Hematological Oncology.

Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.

J. Burke, K. Kolibaba, J. Reeves, 2019, Journal of Clinical Oncology.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

G. Lenz, A. Santoro, A. Nagler, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CLL-116 BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed-Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress).

P. Zinzani, J. Pagel, C. Tam, 2022, Clinical lymphoma, myeloma & leukemia.

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

R. Marcus, P. Zinzani, Jie Jin, 2020 .

Biology and treatment of follicular lymphoma

S. Pileri, E. Sabattini, P. Zinzani, 2009, Expert review of hematology.

Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)

G. Salles, I. Flinn, C. Flowers, 2013 .

Rituximab Combined with M/VACOP-B and Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma (PMLBCL): A Prospective Italian Phase II IIL Study.

R. Foà, A. Levis, P. Zinzani, 2006 .

Early relapse in a patient with Hodgkin’s disease and negative interim FDG-PET

V. Ambrosini, C. Nanni, D. Rubello, 2008, Annals of nuclear medicine.

Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation.

H. Stein, D. Huglo, R. Marcus, 2007, Blood.

Coastal: A phase 3 study of the PI3Kδ inhibitor zandelisib with rituximab (R) versus immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL).

Wenying Huang, P. Zinzani, D. Cunningham, 2021, Journal of Clinical Oncology.

P1123: TEMPO: A PHASE 2, RANDOMIZED, OPEN-LABEL, 2-ARM STUDY COMPARING TWO INTERMITTENT DOSING SCHEDULES OF DUVELISIB IN SUBJECTS WITH INDOLENT NON-HODGKIN LYMPHOMA (INHL)

L. Gordon, I. Flinn, P. Zinzani, 2021, HemaSphere.

Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory Cutaneous T-cell Lymphoma (CTCL)

P. Zinzani, F. Vanaclocha, M. Duvic, 2008 .

Erythroderma and non-Hodgkin T-cell lymphoma: what else, apart from Mycosis Fungoides and Sézary syndrome?

A. Pileri, P. Zinzani, C. Agostinelli, 2017, European Journal of Dermatology.

A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report

P. Zinzani, C. Agostinelli, M. Cavo, 2018, BMC Cancer.

CD38, BCL‐2, PD‐1, and PD‐1L expression in nodal peripheral T‐cell lymphoma: Possible biomarkers for novel targeted therapies?

S. Pileri, R. Fanin, E. Sabattini, 2017, American journal of hematology.